Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RBS-00X
- Development stage
- Unknown
- Lead developer
- RophiBio
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravitreal
01
Overview
RBS-00X is a bispecific antibody biosimilar of faricimab (Vabysmo) being developed by RophiBio for the treatment of ophthalmic diseases, such as neovascular (wet) age-related macular degeneration and diabetic macular edema. It is designed to simultaneously target and inhibit vascular endothelial growth factor-A (VEGF-A) and angiopoietin-2 (Ang-2), thereby stabilizing retinal blood vessels, reducing vascular leakage, and inhibiting pathological angiogenesis. The candidate is currently in early-stage development, with plans for a tailored Phase 3 clinical trial.
- Other names
- Vabysmo biosimilarfaricimab biosimilar
02
Targets
ANGPT2 (Angiopoietin-2)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on RBS-00X.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RBS-00X.